Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1996-03-08
1998-06-30
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
514573, 514912, A61K 31215, A61K 3119
Patent
active
057734712
ABSTRACT:
The present invention provides a method for treatment of optic nerve disorder by the administration of a prostanoic acid compound in an amount effective in treatment of optic nerve disorder to a subject in need of such treatment, by which visual acuity can be recovered.
REFERENCES:
patent: 5001153 (1991-03-01), Ueno et al.
patent: 5221690 (1993-06-01), Sugiyama et al.
patent: 5296504 (1994-03-01), St Jernschantz et al.
Medline Abstract 94120984 (1993). Azuma.
John B. Leslie, M.D. and W. David Watkins, M.D., Ph.D., Eicosanoids in the Central Nervous System, Journal of Neurosurgery, vol. 63, No. 5, 659-668 (1985).
A. Bar-Ilan, N. Naveh, et al., Prostaglandin E.sub.2 Changes in the Retina and Optic Nerve of an Eye with Injured Optic Nerve, Neuroscience, vol. 45, No. 1, 221-225 (1991).
Yasumasa Goh and Junji Kishino, Pharmacological Characterization of Prostaglandin-Related Ocular Hypotensive Agents, Japanese Journal of Opthalmology, vol. 38, No. 3, 236-245 (1994).
Hiida Yoshiki
Hirato Tohru
Mashima Yukihiko
Oguchi Yoshihisa
Osama Hiroyoshi
Fay Zohreh
R-Tech Ueno Ltd.
LandOfFree
Treatment of optic nerve disorder with prostanoic acid compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of optic nerve disorder with prostanoic acid compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of optic nerve disorder with prostanoic acid compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1859822